66 results
The primary objectives of our study are to evaluate safety, toxicity and capability of inducing T cell responses of vaccination with, monocyte-derived donor DC electroporated with mRNA encoding hematopoietic-restricted MiHA in patients who had…
To evaluate LFS after allo HCT in AML/RAEB in complete remission using matched or unrelated donors in comparison to conventional chemotherapy
Objective of the study is to evaluate whether parameters can be identified that predict which graft ultimately prevails following cord blood transplantation after a reduced intensity conditioning regimen in adult patients .In addition engraftment,…
Evaluation of therapeutic safety and clinical efficacy of MSC transplantation in septic shock.
To find out if intravenous MSC is a safe treatment for children with therapy-resistant JIA
To assess if preoxygenation with 100% O2 or preoxygenation with 100% O2 and PEEP are different with respect to the development of atelectasis as determined by lung computed tomography.
To study whether selected allogeneic bone marrow derived MSCs are safe by assessing the composite end point Biopsy Proven Acute Rejection (BPAR)/ graft loss at 12 months
To improve the response rate to treatment of severe acute GVHD (grade II-IV with gut involvement ) by adding infusion of Mesenchymal Stroma Cells to standard high dose prednisolone.
To evaluate the efficacy and safety of eASCs compared to placebo for the treatment of complex fistulas in Crohn*s disease over a 24- and 104-week period.
To investigate the effect of expanded adipose-derived allogeneic adult stem cells (eASCs) on the inflammatory response to intravenous LPS in humans.
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in one…
The primary objectives of our study are to evaluate safety, toxicity and capability of inducing T cell responses of vaccination with, monocyte-derived donor DC transfected with PD-L1/L2 siRNA and electroporated with mRNA encoding hematopoietic-…
To evaluate the efficacy, safety and feasibility of combined immune modulation with rituximab, ITI and MSCs in terms of eradication of FVIII inhibitory activity in hemophilia A patients.
This study will investigate whether bone marrow-derived allogeneic MSCs, as administered by the nasal route, can induce the formation of neuronal tissue and restore brain function in neonates who suffered from perinatal arterial ischemic stroke (…
Objective: To test feasibility and safety of alpha beta T-/CD19 B-cell depleted allo-SCT in high risk or relapsed acute leukaemia / MDS followed by an innate donor lymphocyte infusion (iDLI)
Primary objective of this study is: To assess the efficacy of adjuvant therapy of ALD-101 in accelerating platelet engraftment in patients also receiving a standard unrelated UCBT for treatment of inborn errors of metabolismThe secondary objective…
To assess the safety (incidence of drug-related adverse events) and efficacy of allogeneic ASCs for the treatment of complex perianal Crohn*s fistulas compared to placebo.
Primary objectives: - To evaluate the toxicity and feasibility of a preemptive minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DC vaccination.- To evaluate the effect of a minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DC vaccination on…
- To evaluate the toxicity and feasibility of a preemptive minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DCvaccination.- To evaluate the effect of a minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DC vaccination on the immunestatus of…
The objective is to evaluate safety, toxicity and expansion of intraperitoneally infused UCB-derivedex vivo-generated NK cells in patients diagnosed with recurrent ovarian cancer. Infusion with and without lymphodepleting chemotherapy will be…